Hoag S - Search Results

1

FDA/M-CERSI Co-Processed API Workshop Proceedings.

Schenck L, Patel P, Sood R, Bonaga L, Capella P, Dirat O, Erdemir D, Ferguson S, Gazziola C, Gorka LS, Graham L, Ho R, Hoag S, Hunde E, Kline B, Lee SL, Madurawe R, Marziano I, Merritt JM, Page S, Polli J, Ramanadham M, Sapru M, Stevens B, Watson T, Zhang H. Schenck L, et al. Among authors: hoag s. J Pharm Sci. 2023 Aug;112(8):2069-2078. doi: 10.1016/j.xphs.2023.01.006. Epub 2023 Jan 10. J Pharm Sci. 2023. PMID: 36638959

2

Estimation of capping incidence by indentation fracture tests.

Kuppuswamy R, Anderson SR, Augsburger LL, Hoag SW. Kuppuswamy R, et al. Among authors: hoag sw. AAPS PharmSci. 2001;3(1):E5. doi: 10.1208/ps030105. AAPS PharmSci. 2001. PMID: 11741256 Free PMC article.

3

Spray layering of human immunoglobulin G: Optimization of formulation and process parameters.

Jiang B, Yu D, Zhang Y, Yu H, Feng H, Hoag SW. Jiang B, et al. Int J Pharm. 2021 Dec 15;610:121238. doi: 10.1016/j.ijpharm.2021.121238. Epub 2021 Nov 5. Int J Pharm. 2021. PMID: 34748814

4

Solute diffusion in genetically engineered silk-elastinlike protein polymer hydrogels.

Dinerman AA, Cappello J, Ghandehari H, Hoag SW. Dinerman AA, et al. J Control Release. 2002 Aug 21;82(2-3):277-87. doi: 10.1016/s0168-3659(02)00134-7. J Control Release. 2002. PMID: 12175743

5

Investigation of the physical-mechanical properties of Eudragit(®) RS PO/RL PO and their mixtures with common pharmaceutical excipients.

Dave VS, Fahmy RM, Hoag SW. Dave VS, et al. Among authors: hoag sw. Drug Dev Ind Pharm. 2013 Jul;39(7):1113-25. doi: 10.3109/03639045.2012.714786. Epub 2012 Sep 20. Drug Dev Ind Pharm. 2013. PMID: 22994144

6

Swelling behavior of a genetically engineered silk-elastinlike protein polymer hydrogel.

Dinerman AA, Cappello J, Ghandehari H, Hoag SW. Dinerman AA, et al. Biomaterials. 2002 Nov;23(21):4203-10. doi: 10.1016/s0142-9612(02)00164-3. Biomaterials. 2002. PMID: 12194523

7

Assessment of the critical factors affecting the porosity of roller compacted ribbons and the feasibility of using NIR chemical imaging to evaluate the porosity distribution.

Lim H, Dave VS, Kidder L, Neil Lewis E, Fahmy R, Hoag SW. Lim H, et al. Among authors: hoag sw. Int J Pharm. 2011 May 30;410(1-2):1-8. doi: 10.1016/j.ijpharm.2011.02.028. Epub 2011 Mar 1. Int J Pharm. 2011. PMID: 21371542

8

Open-label dose-extending placebos for opioid use disorder: a protocol for a randomised controlled clinical trial with methadone treatment.

Belcher AM, Cole TO, Greenblatt AD, Hoag SW, Epstein DH, Wagner M, Billing AS, Massey E, Hamilton KR, Kozak ZK, Welsh CJ, Weintraub E, Wickwire EM, Wish ED, Kaptchuk TJ, Colloca L. Belcher AM, et al. Among authors: hoag sw. BMJ Open. 2019 Jun 21;9(6):e026604. doi: 10.1136/bmjopen-2018-026604. BMJ Open. 2019. PMID: 31230007 Free PMC article.

9

Practical limitations of tableting indices.

Kuppuswamy R, Anderson SR, Hoag SW, Augsburger LL. Kuppuswamy R, et al. Among authors: hoag sw. Pharm Dev Technol. 2001 Nov;6(4):505-20. doi: 10.1081/pdt-120000289. Pharm Dev Technol. 2001. PMID: 11775952

10

Influence of polyethylene glycol and povidone on the polymorphic transformation and solubility of carbamazepine.

Nair R, Gonen S, Hoag SW. Nair R, et al. Among authors: hoag sw. Int J Pharm. 2002 Jun 20;240(1-2):11-22. doi: 10.1016/s0378-5173(02)00083-2. Int J Pharm. 2002. PMID: 12062497

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

159 results

Search Page

Filters